Loading AI tools
Stomach acid suppressing medication From Wikipedia, the free encyclopedia
Dexlansoprazole, is a medication which reduces stomach acid.[3] It is used to treat gastroesophageal reflux disease.[3] Effectiveness is similar to other proton pump inhibitors (PPIs).[4] It is taken by mouth.[3]
| |
-lansoprazole-from-xtal-3D-bs-17.png) | |
| Clinical data | |
|---|---|
| Trade names | Kapidex, Dexilant, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a695020 |
| License data | |
| Routes of administration | By mouth |
| Drug class | Proton pump inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Excretion | 50% renal and 47% in the feces[2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.215.667 |
| Chemical and physical data | |
| Formula | C16H14F3N3O2S |
| Molar mass | 369.36 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Common side effects include diarrhea, abdominal pain, and nausea.[3] Serious side effects may include osteoporosis, low blood magnesium, Clostridioides difficile infection, anaphylaxis, and pneumonia.[3] Use in pregnancy and breastfeeding is of unclear safety.[5] It works by blocking H+/K+-ATPase in the parietal cells of the stomach.[3]
Dexlansoprazole was approved for medical use in the United States in 2009.[3] In Canada in 2016, it was the most expensive Proton-pump inhibitor (PPI) available.[4] In 2022, it was the 186th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[6][7]
Dexlansoprazole is used to heal and maintain healing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD).[2] It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often.[8] There is no good evidence that it works better than other PPIs.[4]
The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, bloating, nausea, upper respiratory tract infection, vomiting, and flatulence.[2]
Like lansoprazole, dexlansoprazole permanently binds to the proton pump and blocks it, preventing the formation of gastric acid.[8]
Dexlansoprazole is the (R)-(+)-enantiomer of lansoprazole, which is a racemic mixture of its (R)-(+) and (S)-(−)-enantiomers.[8] The Takeda drug has a dual release pharmaceutical formulation, with two types of granules of dexlansoprazole, each with a coating that dissolves at a different pH level.[8]
Dexlansoprazole ((R)-(+)-lansoprazole) has the same binding affinity to the proton pump as the (S)-enantiomer, but is associated with a three- to five-fold greater area under the plasma drug concentration time curve (AUC) compared with (S)-lansoprazole.[8] With its dual release pharmaceutical formulation, the first quick release produces a plasma peak concentration about one hour after application, with a second delayed release producing another peak about four hours later.[9][10]
Dexlansoprazole was approved in the United States in 2009, in Canada in 2010, and in Mexico in 2011.[8]
Since Kapidex was approved in 2009, there have been reports of dispensing errors because of confusion with the drugs Casodex (bicalutamide) and Kadian (morphine), which have very different uses from Kapidex and from each other. In 2010, the FDA approved a name change for Kapidex to avoid confusion with the two other medications and Takeda began marketing it under the new name Dexilant.[11]
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.
